Monoclonal antibody to cytokeratin VKIALEVEIATY sequence motif reduces plasminogen activation in breast tumour cells

Cancer Letters

Volumn 267, Issue 1, 2008, Pages 75-84

  Doljak, Bojan ^a   Obermajer, Nataša ^a   Jamnik, Polona ^a   Kos, Janko ^a,b  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

^b JO EF STEFAN INSTITUTE   (Slovenia)

Author keywords

Breast cancer; Cytokeratin; Monoclonal antibody; Plasminogen

Indexed keywords

CYTOKERATIN 1; CYTOKERATIN 10; CYTOKERATIN 18; CYTOKERATIN 2; CYTOKERATIN 8; CYTOKERATIN ANTIBODY; EPITOPE; MONOCLONAL ANTIBODY; POLYPEPTIDE; VALYLLYSYLISOLEUCYLALANYLLEUCYLGLUTAMYLVALYLGLUTAMYLISOLEUCYLALANYLTHREONYLTYROSINE;

ALPHA HELIX; AMINO ACID SEQUENCE; AMINO ACID SYNTHESIS; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; BREAST CANCER; CELL INVASION; CELL LYSATE; CONSENSUS SEQUENCE; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOBLOTTING; MASS SPECTROMETRY; MOUSE; NONHUMAN; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; SURFACE PLASMON RESONANCE; TUMOR CELL; TWO DIMENSIONAL ELECTROPHORESIS;

AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MEMBRANE; HUMANS; HYBRIDOMAS; KERATINS; MOLECULAR SEQUENCE DATA; PLASMINOGEN;

MUS;

EID: 45849134882     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.03.006     Document Type: Article

References (33)

1. Moll R., Franke W., Schiller D., Geiger B., and Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 31 (1982) 11-24
2. Coulombe P., and Omary M. 'Hard' and 'soft' principles defining the structure, function and regulation of keratin intermediate filaments. Curr. Opin. Cell Biol. 14 (2002) 110-122
3. Paramio J., and Jorcano J. Beyond structure: do intermediate filaments modulate cell signalling?. Bioessays 24 (2002) 836-844
4. Stigbrand T. The versatility of cytokeratins as tumor markers. Tumour Biol. 22 (2001) 1-3
5. Ku N., Azhar S., and Omary M. Keratin 8 phosphorylation by p38 kinase regulates cellular keratin filament reorganization: modulation by a keratin 1-like disease causing mutation. J. Biol. Chem. 277 (2002) 10775-10782
6. Toivola D., Nieminen M., Hesse M., He T., Baribault H., Magin T., Omary M., and Eriksson J. Disturbances in hepatic cell-cycle regulation in mice with assembly-deficient keratins 8/18. Hepatology 34 (2001) 1174-1183
7. Chu Y., Runyan R., Oshima R., and Hendrix M. Expression of complete keratin filaments in mouse L cells augments cell migration and invasion. Proc. Natl. Acad. Sci. USA 90 (1993) 4261-4265
8. Godfroid E., Geuskens M., Dupressoir T., Parent I., and Szpirer C. Cytokeratins are exposed on the outer surface of established human mammary carcinoma cells. J. Cell Sci. 99 Pt. 3 (1991) 595-607
9. Olofsson M., Ueno T., Pan Y., Xu R., Cai F., van der Kuip H., Muerdter T., Sonnenberg M., Aulitzky W., Schwarz S., Andersson E., Shoshan M., Havelka A., Toi M., and Linder S. Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy. Clin. Cancer Res. 13 (2007) 3198-3206
10. Farmen R., Nordgård O., Gilje B., Shammas F., Kvaløy J., Oltedal S., and Heikkilä R. Bone marrow cytokeratin 19 mRNA level is an independent predictor of relapse-free survival in operable breast cancer patients. Breast Cancer Res. Treat. (2007)
11. Harjaček M., Malenica B., Beketić L., Šimaga S., Čurin-Šerbaec V., Vitale L., and Novak D. Monoclonal antibodies against breast cancer antigen. Period Biol 92 (1990) 128-129
12. Beketić-Oresković L., Sarcević B., Malenica B., and Novak D. Immunocytochemical reactivity of a mouse monoclonal antibody CDI 315B raised against human breast carcinoma. Neoplasma 40 (1993) 69-74
13. Görg A. Two-dimensional electrophoresis. Nature 349 (1991) 545-546
14. Yan J., Wait R., Berkelman T., Harry R., Westbrook J., Wheeler C., and Dunn M. A modified silver staining protocol for visualization of proteins compatible with matrix-assisted laser desorption/ionization and electrospray ionization-mass spectrometry. Electrophoresis 21 (2000) 3666-3672
15. Kos J., Smid A., Krasovec M., Svetic B., Lenarcic B., Vrhovec I., Skrk J., and Turk V. Lysosomal proteases cathepsins D, B, H, L and their inhibitors stefins A and B in head and neck cancer. Biol. Chem. Hoppe Seyler 376 (1995) 401-405
16. López-Alemany R., Longstaff C., Hawley S., Mirshahi M., Fábregas P., Jardí M., Merton E., Miles L., and Félez J. Inhibition of cell surface mediated plasminogen activation by a monoclonal antibody against alpha-Enolase. Am. J. Hematol. 72 (2003) 234-242
17. Pluskota E., Soloviev D., Bdeir K., Cines D., and Plow E. Integrin alphaMbeta2 orchestrates and accelerates plasminogen activation and fibrinolysis by neutrophils. J. Biol. Chem. 279 (2004) 18063-18072
18. Rakha E., El-Sayed M., Green A., Lee A., Robertson J., and Ellis I. Prognostic markers in triple-negative breast cancer. Cancer 109 (2007) 25-32
19. Gires O., Andratschke M., Schmitt B., Mack B., and Schaffrik M. Cytokeratin 8 associates with the external leaflet of plasma membranes in tumour cells. Biochem. Biophys. Res. Commun. 328 (2005) 1154-1162
20. Ditzel H., Garrigues U., Andersen C., Larsen M., Garrigues H., Svejgaard A., Hellström I., Hellström K., and Jensenius J. Modified cytokeratins expressed on the surface of carcinoma cells undergo endocytosis upon binding of human monoclonal antibody and its recombinant Fab fragment. Proc. Natl. Acad. Sci. USA 94 (1997) 8110-8115
21. Hembrough T., Li L., and Gonias S. Cell-surface cytokeratin 8 is the major plasminogen receptor on breast cancer cells and is required for the accelerated activation of cell-associated plasminogen by tissue-type plasminogen activator. J. Biol. Chem. 271 (1996) 25684-25691
22. Steinert P., Steven A., and Roop D. Structural features of epidermal keratin filaments reassembled in vitro. J. Invest. Dermatol. 81 (1983) 86s-90s
23. Johansson A., Sandström P., Ullén A., Behravan G., Erlandsson A., Levi M., Sundström B., and Stigbrand T. Epitope specificity of the monoclonal anticytokeratin antibody TS1. Cancer Res. 59 (1999) 48-51
24. Hembrough T., Kralovich K., Li L., and Gonias S. Cytokeratin 8 released by breast carcinoma cells in vitro binds plasminogen and tissue-type plasminogen activator and promotes plasminogen activation. Biochem. J. 317 Pt 3 (1996) 763-769
25. Ranson M., Andronicos N., O'Mullane M., and Baker M. Increased plasminogen binding is associated with metastatic breast cancer cells: differential expression of plasminogen binding proteins. Br. J. Cancer 77 (1998) 1586-1597
26. Kralovich K., Li L., Hembrough T., Webb D., Karns L., and Gonias S. Characterization of the binding sites for plasminogen and tissue-type plasminogen activator in cytokeratin 8 and cytokeratin 18. J. Protein Chem. 17 (1998) 845-854
27. Herren T., Swaisgood C., and Plow E. Regulation of plasminogen receptors. Front Biosci. 8 (2003) d1-d8
28. Miles L., Dahlberg C., Levin E., and Plow E. Gangliosides interact directly with plasminogen and urokinase and may mediate binding of these fibrinolytic components to cells. Biochemistry 28 (1989) 9337-9343
29. Miles L., Dahlberg C., Plescia J., Felez J., Kato K., and Plow E. Role of cell-surface lysines in plasminogen binding to cells: identification of alpha-enolase as a candidate plasminogen receptor. Biochemistry 30 (1991) 1682-1691
30. Hajjar K., Harpel P., Jaffe E., and Nachman R. Binding of plasminogen to cultured human endothelial cells. J. Biol. Chem. 261 (1986) 11656-11662
31. Hall S., VandenBerg S., and Gonias S. Plasminogen carbohydrate side chains in receptor binding and enzyme activation: a study of C6 glioma cells and primary cultures of rat hepatocytes. J. Cell Biochem. 43 (1990) 213-227
32. Kopitar-Jerala N., Bestagno M., Fan X., Novak-Despot D., Burrone O., Kos J., Skrk J., and Gubensek F. Molecular cloning and chimerisation of CDI 315B monoclonal antibody. Pflugers Arch. 439 (2000) R79-R80
33. Obermajer N., Kocbek P., Repnik U., Kuznik A., Cegnar M., Kristl J., and Kos J. Immunonanoparticles - an effective tool to impair harmful proteolysis in invasive breast tumor cells. FEBS J. 274 (2007) 4416-4427